Brief: Autolus Therapeutics’ Car T Therapy Aucatzyl® (Obecabtagene Autoleucel) Granted European Marketing Authorization For Adult Patients
21/07/2025 12:03
July 21 (Reuters) - Autolus Therapeutics PLC 6A3Ay.F: AUTOLUS THERAPEUTICS’ CAR T THERAPY AUCATZYL® (OBECABTAGENE AUTOLEUCEL) GRANTED EUROPEAN MARKETING AUTHORIZATION FOR ADULT PATIENTS (AGE 26 AND OLDER) WITH RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL) Source text: ID:nGNX3XKC04 Further company coverage: [6A3Ay.F] ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Autolus Therapeutics
See all newsBrief: Autolus Therapeutics PLC Unit Enters Master Service Agreement With AGC Biologics
Brief: Autolus Therapeutics Appoints Ryan Richardson To Board Of Directors
Brief: Nice Recommends Aucatzyl As A Treatment Option For Adult Patients With Lymphoblastic Leukemia
Brief: Autolus Therapeutics’ Car T Therapy Aucatzyl® (Obecabtagene Autoleucel) Granted European Marketing Authorization For Adult Patients
Brief: Autolus Therapeutics Announces Inducement Grants